Skip to main content
Atrás
Watch Compare

IGC Pharma, Inc.

Calidad de datos: 100%
IGC
NYSE Manufacturing Chemicals
$0.32
▲ $0.01 (3.19%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-0.82%

Crecimiento

Revenue Growth (5Y)
-0.82%
Below sector avg (1.72%)
Revenue (1Y)-35.39%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-48.99%
Above sector avg (-54.47%)
ROIC-91.75%
Net Margin-493.04%
Op. Margin-1192.19%

Seguridad

Debt / Equity
0.02
Below sector avg (0.30)
Current Ratio1.32
Interest Coverage-2797.67

Valoración

PE (TTM)
-8.12
Below sector avg (-1.50)
P/B Ratio3.48
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -0.82% annually over 5 years
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -5.49 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 34.57%
Capital efficient — spends only 2.70% of revenue on capex

Price History

Tendencias Financieras

Precio Objetivo de Analistas

2 analistas
Buy
+1189.1%
upside to target
Actual
$0.32
Consensus Target
$4.13
$3.00
Mín
$5.25
Máx
Pronóstico
EPS Futuro
-$0.09

Sorpresas de Ganancias

EPS
Reported Estimate Forecast
Next: Q1 2026 · Rev Est: 0.0
Q42024 Q12025 Q22025 Q32025 Q1 '26
Reported -$0.02 -$0.01 -$0.02 -$0.02 —
Estimate -$0.03 -$0.02 -$0.03 -$0.02 —
Sorpresa +33.33% +50.00% +20.00% 0.00% —

Growth

Rev 5Y: -0.82% · Earnings 1Y: N/A
Revenue Growth (1Y) -35.39% Revenue Growth (3Y) -2.33%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0.82% Earnings Growth (5Y) N/A

Profitability

ROE: -48.99% · Net Margin: -493.04%
Revenue (TTM) 704,000.0 Net Income (TTM) -3.47 M
ROE -48.99% ROA -39.25%
Gross Margin 26.85% Operating Margin -1192.19%
Net Margin -493.04% Free Cash Flow (TTM) -5.49 M
ROIC -91.75% FCF Growth (3Y) N/A

Safety

D/E: 0.02 · Current: 1.32
Debt / Equity 0.02 Current Ratio 1.32
Interest Coverage -2797.67 Asset Turnover 0.08
Working Capital 490,000 Tangible Book Value 3.21 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -8.12 · EV/EBITDA: N/A
P/E Ratio -8.12 Forward P/E N/A
P/B Ratio 3.48 P/S Ratio 40.05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19.46%
Market Cap 28.20 M Enterprise Value 27.23 M

Per Share

EPS: -0.03 · FCF/Share: -0.06
EPS (Diluted TTM) -0.03 Revenue / Share 0.01
FCF / Share -0.06 OCF / Share -0.06
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 158.11% · CapEx/Rev: 2.70%
CapEx / Revenue 2.70% FCF Conversion 158.11%
SBC-Adj. FCF -14.49 M Growth Momentum -34.57

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 869,000.0 1.35 M 911,000.0 397,000.0 898,000.0
Net Income -4.15 M -13.00 M -11.51 M -15.02 M -8.81 M
EPS (Diluted) -0.05 — — — —
Gross Profit 297,000.0 733,000.0 442,000.0 194,000.0 113,000.0
Operating Income -7.75 M -9.80 M -11.57 M -15.43 M -8.72 M
EBITDA — — — — —
R&D Expenses 3.92 M 3.77 M 3.46 M 2.33 M 929,000.0
SG&A Expenses 4.12 M 6.76 M 8.55 M 13.29 M 7.91 M
D&A 324,000.0 637,000.0 657,000.0 651,000.0 478,000.0
Interest Expense 4,000.0 5,000.0 5,000.0 5,000.0 3,000.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.71 M 9.90 M 17.18 M 26.83 M 35.87 M
Total Liabilities 2.29 M 2.58 M 2.27 M 2.94 M 3.06 M
Shareholders' Equity 7.42 M 7.32 M 14.91 M 23.89 M 32.80 M
Total Debt 134,000.0 140,000.0 144,000.0 147,000.0 580,000.0
Cash & Equivalents 900,000.0 1.20 M 3.20 M 10.46 M 14.55 M
Current Assets 1.79 M 3.71 M 6.47 M 15.11 M 23.52 M
Current Liabilities 2.16 M 2.34 M 1.90 M 2.44 M 2.37 M

Comparación con Pares

vs mediana del sector Manufacturing (1605 pares)
Métrica Acción Mediana del Sector
P/E -8.1 -1.5
P/B 3.5 1.6
ROE % -49.0 -54.5
Net Margin % -493.0 -41.5
Rev Growth 5Y % -0.8 1.7
D/E 0.0 0.3